Cerebrospinal fluid viral breakthrough in two HIV-infected subjects on darunavir/ritonavir monotherapy

Scandinavian Journal of Infectious Diseases

Volumn 44, Issue 12, 2012, Pages 997-1000

  Gisslén, Magnus ^a   Fuchs, Dietmar ^b   Hagberg, Lars ^a   Svennerholm, Bo ^c   Zetterberg, Henrik ^c,d  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cerebrospinal fluid; Darunavir; HIV; Monotherapy; Neuronal injury

Indexed keywords

ABACAVIR; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE; ENFUVIRTIDE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEOPTERIN; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CASE REPORT; CAUCASIAN; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID; DRESS SYNDROME; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FACIAL NERVE PARALYSIS; FEMALE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUMBAR PUNCTURE; MALE; MONOTHERAPY; NEUROFILAMENT; RASH; TREATMENT DURATION; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CEREBROSPINAL FLUID; FEMALE; HIV INFECTIONS; HUMANS; MALE; RITONAVIR; SULFONAMIDES;

EID: 84874120932     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2012.690526     Document Type: Article

References (18)

1. Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study. Neurology 2010;75:2087-96.
2. Simioni S, Cavassini M, Annoni JM, Rimbault Abraham A, Bourquin I, Schiffer V, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010;24:1243-50.
3. Gisslen M, Price RW, Nilsson S. The defi nition of HIV-associated neurocognitive disorders: Are we overestimating the real prevalence? BMC Infect Dis 2011;11:356.
4. Hagberg L, Cinque P, Gisslen M, Brew BJ, Spudich S, Bestetti A, et al. Cerebrospinal fluid neopterin: An informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther 2010;7:15.
5. Mellgren A, Price RW, Hagberg L, Rosengren L, Brew BJ, Gisslen M. Antiretroviral treatment reduces increased CSF neurofi lament protein (NFL) in HIV-1 infection. Neurology 2007;69:1536-41.
6. Mellgren A, Antinori A, Cinque P, Price RW, Eggers C, Hagberg L, et al. Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment. Antivir Ther 2005; 10:701-7.
7. Clumeck N, Rieger A, Banhegyi D, Schmidt W, Hill A, Van Delft Y, et al. 96 week results from the MONET trial: A randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA - 50 copies/ml at baseline. J Antimicrob Chemother 2011;66:1878-85.
8. Katlama C, Valantin MA, Algarte-Genin M, Duvivier C, Lambert-Niclot S, Girard PM, et al. Effi cacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: A randomized open-label, noninferiority trial, MONOI-ANRS 36. AIDS 2010;24:2365-74.
9. Gazzard B, Hill A, Anceau A. Cost-effi cacy analysis of the MONET trial using UK antiretroviral drug prices. Appl Health Econ Health Policy 2011;9:217-23.
10. Norgren N, Rosengren L, Stigbrand T. Elevated neurofi lament levels in neurological diseases. Brain Res 2003;987: 25-31.
11. Yilmaz A, Verhofstede C, D' A volio A, Watson V, Hagberg L, Fuchs D, et al. Treatment intensifi cation has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy. J Acquir Immune Defi c Syndr 2010;55:590-6.
12. Maruff P, Thomas E, Cysique L, Brew B, Collie A, Snyder P, et al. Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex. Arch Clin Neuropsychol 2009;24: 165-78.
13. Gutmann C, Cusini A, Gunthard HF, Fux C, Hirschel B, Decosterd LA, et al. Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: The role of compartment and CD4-nadir. AIDS 2010;24:2347-54.
14. Vernazza P, Daneel S, Schiffer V, Decosterd L, Fierz W, Klimkait T, et al. The role of compartment penetration in PImonotherapy: The Atazanavir-Ritonavir Monomaintenance (ATARITMO) trial. AIDS 2007;21:1309-15.
15. Abdulle S, Mellgren A, Brew BJ, Cinque P, Hagberg L, Price RW, et al. CSF neurofi lament protein (NFL) - a marker of active HIV-related neurodegeneration. J Neurol 2007;254: 1026-32.
16. Gisslen M, Hagberg L, Brew BJ, Cinque P, Price RW, Rosengren L. Elevated cerebrospinal fluid neurofi lament light protein concentrations predict the development of AIDS dementia complex. J Infect Dis 2007;195:1774-8.
17. Canestri A, Lescure FX, Jaureguiberry S, Moulignier A, Amiel C, Marcelin AG, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis 2010;50:773-8.
18. Eden A, Fuchs D, Hagberg L, Nilsson S, Spudich S, Svennerholm B, et al. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis 2010;202:1819-25.